Special Issue "Care and Management of Hemoglobinopathies, a Changing Global Health Problem: Guidelines and Recommendations from the Italian Society of Thalassemia and Hemoglobinopathies (SITE)"

Dear Colleagues,

The inherited disorders of hemoglobin (Hb), which include sickle cell disease and thalassemia syndromes, are the most common monogenic diseases. Population movements have led to a much wider distribution of the βS and β thalassemia alleles, particularly in North America and Western Europe, and in spite of the significant advances in treatment, they are likely to remain a serious global health problem for the foreseeable future. On the one hand, improved care has led to a prolonged survival of patients, especially in the case of thalassemia, which, as a counteract, has resulted in new complications and emerging issues. On the other side, innovative approaches based on new technology promise to cure hemoglobinopathies beyond hematopoietic stem cell transplantation or to significantly reduce the burden of the disease, posing the problem of identifying and selecting the patients to whom they are to be offered safely and with the highest guarantee of effectiveness. The Italian Society of Thalassemia and Hemoglobinopathies (SITE) aims to ameliorate the lives of children and adults with haemoglobinopathies by producing and researching the most relevant and updated evidence on key aspects of hemoglobinopathies, including the screening of carriers, prenatal diagnosis of disease and early recognition of patients, the management of emerging complications, and the identification of criteria for the selection of patients who may have priority access to new therapies. This Special Issue aims to collect and disseminate the principles and most recent guidelines and recommendations issued by the Italian Society of Thalassemia and Hemoglobinopathies (SITE).

Dr. Raffaella Origa
Dr. Valeria Maria Pinto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• sickle cell disease
• thalassemia
• hemoglobinopathies
• innovative drugs
• gene therapy